Home > News & Media > News
Communication starts here.
2017.01
TWi Settles Patent Challenge Relating to Its Paragraph IV ANDA Filing for a Generic Equivalent to Restasis
2016.12
TWi Bio is officially listed on Emerging Market of Taipei Exchange
2016.11
TWi announces the disposal of its equity investment at Visum
2016.11
TWi Settles Patent Challenge Relating to Its Paragraph IV ANDA Filing for a Generic Equivalent to Androgel 1.62%
2016.11
Par Pharmaceutical Drops Appeal And Agrees To Pay TWi Pharmaceuticals The Full Amount Of Damages Awarded By The District Court
2016.10
Par Pharmaceutical, Inc filed its notice of appeal for the distribution of injunction bonds in generic Megace ES patent suit
2016.09
TWi Pharmaceuticals Awarded US$12.7 Million In Generic MEGACE ES® Patent Suit
2016.09
TWi Confirms Patent Challenge Relating to Its Paragraph IV ANDA Filing for a Generic Equivalent to Androgel 1.62%
2015.09
TWi Pharmaceuticals Issues GDR and raised NT$ 2.83 Billion
2015.09
TWi Pharmaceuticals President & CEO Ms. Tina Guilder will resign from her current roles and Chairman Dr. Chih-Ming Chen will become interim President & CEO

 

Pages:1 - 2 - 3 - 4 - 5 - 6« Pre · Next »